Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc., a Delaware corporation, on February 9, 2026. The company is listed on the Nasdaq Capital Market under the symbols BIAF (Common Stock) and BIAFW (Warrants). The filing reports a corporate governance event rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement filing (such as a 10-K or 10-Q) and contains no quantitative financial data.
Material Changes
The material change reported is the appointment of three new members to the company's Medical and Scientific Advisory Board on February 9, 2026. The appointees are:
- David Ost, MD, MPH
- Daniel Sterman, MD
- J. Scott Ferguson, MD
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors. The primary purpose of the report is to disclose the advisory board appointments via a press release attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the credentials and prior affiliations of the newly appointed advisory board members (Dr. Ost, Dr. Sterman, and Dr. Ferguson).
- Review the attached press release (Exhibit 99.1) for details on the scope of the advisory board's role.
- Check recent 10-Q or 10-K filings for the most current financial position, as this 8-K contains no financial data.